Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2024-04-20
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG?
2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?
Participants will:
Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
99mTc-CNDG Injection in the Diagnosis of Malignant Tumors
NCT06030817
FBY PET/CT in Patients With Brain Tumors
NCT03980431
Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
NCT07023640
Clinical Applications of (S)-[18F]FBFP PET/CT in Healthy Volunteers and Patients With Central Nervous System Diseases
NCT05335200
99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients
NCT01737112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intracranial tumor
99mTc-CNDG SPECT/CT
FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
99mTc-CNDG SPECT/CT
FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be at least 18 years old;
* The final pathological results could be obtained by surgery or biopsy;
* Informed consent and the ability to be followed up;
Exclusion Criteria
* Severe liver or kidney disease (serum creatinine level \>3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
* Severe hypersensitivity or hypersensitivity to radiocontrast agents;
* Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
* Patients receiving radiotherapy and chemotherapy;
* Being pregnant or breastfeeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-DG-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.